Medical Condition

head and neck squamous cell carcinoma

Total Trials

22

Recruiting Now

22

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for head and neck squamous cell carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — head and neck squamous cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for head and neck squamous cell carcinoma?

ClinicalMetric currently tracks 22 actively recruiting clinical trials for head and neck squamous cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 22. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for head and neck squamous cell carcinoma?

head and neck squamous cell carcinoma research spans Phase 1 (11 trials), Phase 2 (13 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a head and neck squamous cell carcinoma clinical trial?

Eligibility criteria for head and neck squamous cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

AbbVie 1 trial

NRG Oncology 1 trial

Beijing Tongren Hospital 1 trial

Erasmus Medical Center 1 trial

Yuankai Shi 1 trial

head and neck squamous cell carcinoma

Frequently Asked Questions — head and neck squamous cell carcinoma Clinical Trials

Recruiting Clinical Trials

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Dose Escalation Using Hypoxia-adjusted Radiotherapy

First in Human Study of SIM0610 in Solid Tumors

Study of CHS-114 in Participants With Advanced Solid Tumors

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors